Copenhagen, Denmark; May 10, 2010 – Genmab A/S (OMX: GEN) announced today that four abstracts have been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-8 in Chicago, Illinois. Two additional abstracts have been accepted for publication.
Ofatumumab – Poster session, June 4 from 2:00 PM to 6:00 PM CDT
Abstract #8042 Ofatumumab Combined with CHOP in Previously Untreated Patients with Follicular Lymphoma (FL).
Ofatumumab – Poster session, June 5 from 8:00 AM to 12:00 PM CDT
Abstract #8095 Activity of ofatumumab (O), a fully human monoclonal antibody (mAb) targeting CD20, against rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), lymphoma xenografts, and primary tumor cells derived from patients with B-cell lymphoma.
Ofatumumab – Poster session, June 7 from 2:00 PM to 6:00 PM CDT
Abstract #6520 Chemoimmunotherapy with Ofatumumab, Fludarabine and Cyclophosphamide (O-FC) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).
Ofatumumab – Publication on-line only
Abstract #e18525 Phase I Study of Ofatumumab in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
Zalutumumab – Publication on-line only
Abstract #e13102 Role of ADCC in the in vivo Anti-tumor Effects of Zalutumumab, a Human Anti-EGF Receptor Antibody.
The full abstracts will be available at www.asco.org on May 20, 2010 at 6:00 PM (EDT).
Genmab will also present the following, which was accepted as a late breaking abstract:
Zalutumumab – Oral Abstract session, June 7 from 3:00 PM to 6:00 PM CDT
Abstract #LBA5506 An Open-Label, Randomized, Phase III Trial of Zalutumumab, a Human Monoclonal EGF Receptor Antibody, Versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-Based Chemotherapy (ZALUTE).
This full abstract will be available on June 5, 2010 at 8:00 AM (EDT). This abstract will also be featured at the 2010 Best of ASCO San Francisco Meeting, July 16-17, 2010.
About ofatumumab
Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre‑B‑ to mature B‑lymphocyte) and on B‑cell CLL. The CD20 molecule is not shed from the cell surface and is not internalized following antibody binding.
About zalutumumab
Zalutumumab is a novel, investigational, high-affinity, human antibody that targets the Epidermal Growth Factor receptor (EGFr), a molecule overexpressed on the surface of many cancer cells and that is a well validated target. Zalutumumab is in development to treat head and neck cancer and has received Fast Track designation from the FDA for advanced, metastatic and/or unresectable SCCHN that has progressed following standard platinum-based chemotherapy.
Under the FDA Modernization Act of 1997, Fast Track designation means that FDA will take such actions as are appropriate to expedite the development and review of the application for approval of such product. FDA may also evaluate for filing and commence review of portions of an application for approval of a Fast Track product under certain conditions.